CDMO Yposkesi will increase its current capacity for gene therapy vectors as part of the French government’s “Plan de Relance” program.
Yposkesi, a development and manufacturing contract organization (CDMO) for companies developing cell and gene therapies, announced in a press release dated June 29, 2021 that its bioproduction project has been selected for the initiative of the French government “Plan de Relance”, which is a stimulus plan aimed at making the national bioproduction industry strategically more robust and economically resilient.
Yposkesi invests 5 million euros (US $ 6 million) in its “Boost” project to develop a new generation 1000-L platform, good manufacturing practices (GMP) with optimized manufacturing and control processes for efficient production of viral vectors from thawing of cells to aseptic filling of the final product. As drug developers advance gene therapy treatments from clinical batches to commercial batches, larger scale viral vector capability is needed, the company noted in the press release.
“Yposkesi is proud that our Boost project has been selected for funding under the French government’s ‘Plan de Relance’ program,” said Alain Lamproye, Executive Chairman of Yposkesi, in the press release. “The establishment of a large-scale GMP production line will allow us to achieve significant economies of scale and reduce production costs, while shortening the production time of equal amounts of active substances. Our goal is to help underserved patient populations access advanced therapies. “
The company is currently producing batches of viral vectors in two 200 L bioreactors. After the expansion, one of its four production suites will be able to produce batches at the scale of a 1000 L bioreactor, for sections of upstream production and downstream purification. The company will also increase its bottle filling capacity. Modeling tools will facilitate process optimization.
“The deployment of new infrastructures and their optimal use cannot be done without technological innovation,” added Lamproye. “Part of this project will focus on the construction in silico tools for analyzing and modeling the data generated to optimize, as well as better control and make predictions about our processes.
The company announced earlier in June 2021 that it was building a second cell and gene therapy manufacturing facility at its campus in Corbeil-Essonnes, France.